Abnormal intracellular signaling contributes to carcinogenesis and may represent novel therapeutic targets. mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) overexpression is associated with aggressive prostate cancer. In this study, we examined the role of extracellular signal-regulated kinase (ERK5, an MAPK and specific substrate for MEK5) in prostate cancer. ERK5 immunoreactivity was significantly upregulated in high-grade prostate cancer when compared to benign prostatic hyperplasia (Po0.0001). Increased ERK5 cytoplasmic signals correlated closely with Gleason sum score (Po0.0001), bony metastases (P ¼ 0.0044) and locally advanced disease at diagnosis (P ¼ 0.0023), with a weak association with shorter disease-specific survival (P ¼ 0.036). A subgroup of patients showed strong nuclear ERK5 localization, which correlated with poor diseasespecific survival and, on multivariant analysis, was an independent prognostic factor (Po0.0001). Analysis of ERK5 expression in matched tumor pairs (before and after hormone relapse, n ¼ 26) revealed ERK5 nuclear expression was significantly associated with hormoneinsensitive disease (P ¼ 0.0078). Similarly, ERK5 protein expression was increased in an androgen-independent LNCaP subline. We obtained the following in vitro and in vivo evidence to support the above expression data: (1) cotransfection of ERK5wt and MEK5D constructs in PC3 cells results in predominant ERK5 nuclear localization, similar to that observed in aggressive clinical disease; (2) ERK5-overexpressing PC3 cells have enhanced proliferative, migrative and invasive capabilities in vitro (Po0.0001), and were dramatically more efficient in forming tumors, with a shorter mean time for tumors to reach a critical volume of 1000 mm 3 , in vivo (Po0.0001); (3) the MEK1 inhibitor, PD184352, blocking ERK1/2 activation at low dose, did not suppress proliferation but did significantly decrease proliferation at a higher dose required to inhibit ERK5 activation. Taken together, our results establish the potential importance of ERK5 in aggressive prostate cancer.
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Introduction
Prostate cancer (CaP) is the most commonly diagnosed cancer and the second most frequent cause of cancerrelated death in men in the Western world (Jemal et al., 2005) . CaP is usually androgen dependent and the majority will regress upon treatment with androgen ablation. Unfortunately, about 20% of patients do not show a favorable response, and even among the responders, there is an overall risk of 80% to develop relapsed cancer at a median period of 24 months with hormone manipulation. Therefore, better prognostic markers will facilitate stratification of patients to different treatment protocols aimed at improving survival outcome.
The family of mitogen-activated protein kinases (MAPKs) plays an essential role in the transduction of extracellular signals to cytoplasmic and nuclear effectors. MAP kinase kinases (MEKs/MAPKKs) represent protein kinases upstream of MAPKs, critically controlling cellular proliferation and apoptosis. Mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) is the most recently identified MAPKK and specifically activates ERK5, also known as Big MAP kinase 1 (English et al., 1995; Zhou et al., 1995) . The ability of inhibitors of the classical MAPK (ERK1/2) cascade to block ERK5 activation suggested that ERK5 might regulate some cellular functions originally attributed to ERK1/2. The MEK5/ERK5 pathway is required for epidermal growth factor (EGF)-induced proliferation (Kato et al., 1998) and connexin 43 gap junction communication (Cameron et al., 2003) . ERK5 is almost twice the size of the other MAPKs (815 amino acids). Its unique C-terminal tail contains a myocyte enhancer factor 2 (MEF2)-interacting domain and a potent transcriptional activation domain (Kasler et al., 2000) . The activity of several transcriptional factors has been shown to be regulated by ERK5, including MEF2, c-Fos and Fra-1, Sap-1, c-Myc and nuclear factor-kB (Kato et al., 1997; English et al., 1998; Kamakura et al., 1999; Chiariello et al., 2000; Terasawa et al., 2003) . It plays a key role in embryogenesis: ERK5 knockout mice embryos die between day 9.5 and 11.5 due to severe cardiovascular defects (Regan et al., 2002; Sohn et al., 2002) whereas mice lacking ERK1 develop normally (Pages et al., 1999; Selcher et al., 2001) . A recent study has shown that MEK5 knockout mice also die, at approximately embryonic day 10.5 (Wang et al., 2005) . Also of interest, recently in vivo studies (Matrigel plug assays and xenografts in ERK5 knockout mice) revealed requirement for ERK5 in neovascularization (Hayashi et al., 2005) . We have previously shown upregulated MEK5 expression in CaP (Mehta et al., 2003) . Activation of MEK5 signaling induced proliferation (Po0.0001), motility (P ¼ 0.0001) and invasion in LNCaP CaP cells (Po0.0001). In this study, we further explore the role of ERK5, the specific substrate for MEK5, in CaP.
Results

ERK5 protein expression in resected human prostate cancer
Normal and hyperplastic glands in the benign prostatic hyperplasia (BPH) group demonstrated either negative (n ¼ 2) or weak cytoplasmic staining (n ¼ 18); ERK5 immunoreactivity was mainly localized to the glandular epithelium with patchy areas of weak stromal immunoreactivity ( Figure 1a ). When compared with BPH, cytoplasmic ERK5 expression was significantly upregulated in the malignant epithelium (Mann-Whitney U-test, Po0.0001) (Figures 1b and c) . Increasing ERK5 expression is associated with less differentiated tumors: (1) the Kruskal-Wallis test demonstrated a significant association of ERK5 cytoplasmic immunoreactivity with Gleason sum score (Po0.0001) ( Figure 2a) ; (2) linear regression analysis revealed a strong correlation between ERK5 cytoplasmic protein expression and increasing Gleason sum score (Po0.0001; r ¼ 0.998). We then compared ERK5 cytoplasmic expression with our previous data on MEK5 cytoplasmic expression (matched cases, n ¼ 75) (Mehta et al., 2003) . Linear regression demonstrated a significant correlation between ERK5 and MEK5 cytoplasmic expression (two sided P ¼ 0.0053; r ¼ 0.91) (Figure 2b ). There was also a significant correlation between ERK5 cytoplasmic expression and the presence of bone metastases (P ¼ 0.0044) and extracapsular (locally advanced) disease (P ¼ 0.0023). In our clinical series, with median follow-up of 42 months (range 0.5-126), increasing cytoplasmic ERK5 immunoreactivity was significantly associated with an overall poor patient prognosis, comparing low-and intermediate-expression groups with the high-expression group (P ¼ 0.036, Kaplan-Meier and log-rank analyses) (Figure 2c) . Further, statistical analysis revealed that ERK5 cytoplasmic expression did not relate to serum prostatespecific antigen (PSA) levels (P ¼ 0.295).
ERK5 nuclear staining is an independent prognostic marker in prostate cancer Of particular interest, strong nuclear ERK5 signals were noted in 15 of the 81 CaP cases (Figure 1d ). This was in direct contrast to absent or scant nuclear staining in the other 66 cases of CaP and BPH controls (n ¼ 20). The presence of nuclear ERK5 overexpression is strongly associated with poor patient prognosis (Po0.0001, Kaplan-Meier and log-rank analyses) (Figure 2d ). Furthermore, focusing on poorly differentiated tumors, strong ERK5 nuclear expression remains significantly associated with poor survival outcome, irrespective of Gleason score (P ¼ 0.0008, Kaplan-Meier and log-rank analyses) (Figure 2e ) or presence of strong ERK5 cytoplasmic intensity (P ¼ 0.0052, Kaplan-Meier and log-rank analyses) (Figure 2f ). Multivariate analysis was carried out using Cox regression for survival data, where Gleason sum score, ERK5 cytoplasmic staining intensity and presence of ERK5 nuclear expression were included in the analysis. ERK5 cytoplasmic expression did not provide any further independent prognostic information, while ERK5 nuclear expression was shown to be an independent prognostic marker in CaP (Po0.0001).
Upregulated ERK5 expression in androgen-independent prostate cancer Analysis of ERK5 expression in matched tumor pairs revealed that the presence of ERK5 nuclear expression is significantly associated with the transition from hormone-sensitive to hormone-insensitive disease (P ¼ 0.0078) (Figures 1e and f) . Nonsignificant trends were seen with stronger ERK5 cytoplasmic expression in hormone relapsed disease (P ¼ 0.064). This was further investigated by performing western blot analysis for ERK5 protein expression on lysates from the androgen-dependent CaP cell line, LNCaP, and its androgen-independent derivative, LNCaP-AI. The androgen-independent LNCaP-AI cells showed increased ERK5 protein expression compared to the parental cells (Figure 3a) .
Localization of ERK5 expression in human prostate cancer To evaluate localization of ERK5 expression in human CaP cells, we carried out indirect ERK5 immunofluorescence experiments on the androgen-dependent cell line LNCaP, the androgen-independent derivative LNCaP-AI, and the well-characterized androgen-independent PC3 cell line. Endogenous ERK5 protein was noted to be localized in the cytoplasm in these three cell lines. However, when PC3-ERK5-expressing cells were cultured in optimal conditions, upregulated ERK5 immunoreactivity localized to both nuclear and cytoplasm, consistent with the observation on clinical tumors (Figure 3b ). We therefore hypothesized that ERK5 nuclear localization requires optimal growth stimulation in addition to upregulated ERK5 expression.
We applied two approaches to test this hypothesis: the use of exogenous EGF challenge and the introduction of constitutively active MEK5 by transfection (pcMEK5D). In unstimulated PC3-ERK5 cells, ERK5 was observed to reside in the cytoplasm (Figure 3c ). 
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Following EGF stimulation, ERK5 trafficked into the nucleus producing a punctate appearance, peaking at 10 min. Furthermore, PC3 cells transfected with green fluorescent protein (GFP)-ERK5 alone showed strong cytoplasmic or perinuclear fluorescence. However, cotransfection of the GFP-ERK5 and pcMEK5D resulted in predominant ERK5 nuclear localization ( Figure 3d ). The cytoplasmic location of endogenous ERK5 protein in LNCaP-AI cells therefore suggests the requirement of additional in vitro factors for ERK5 nuclear localization.
Overexpression of ERK5 enhances prostate carcinogenesis
To test if proliferation is driven by overexpression of ERK5 in human CaP, WST-1 assays were performed on PC3 cells stably overexpressing ERK5 (PC3-ERK5 cells). The proliferative index of ERK5-overexpressing cells was 2.7 fold greater than that of PC3 cells stably transfected with the vector alone (Po0.0001) ( Figure 4a ). Migration assays were performed on the ERK5-overexpressing PC3 cells, with an increase of the migrative index by 3.4 fold in the ERK5-overexpressing cells (Po0.0001) ( Figure 4b ). Similarly, invasion assays revealed that the invasive index of ERK5-overexpressing cells was 5.2 fold greater than empty vector control (Po0.0001) ( Figure 4c ). In addition to the above PC3-ERK5 cells (Clone no. 9), three other clones were isolated and confirmed to have upregulated invasive capability ( Supplementary Figures 1 and 2 ).
With an in vivo growth study using PC3-ERK5 and PC3-EmptyVector cells as subcutaneous xenografts, PC3-ERK5 cells were dramatically more efficient in forming tumors, with a shorter mean time for tumors to reach a critical volume of 500 mm 3 (Po0.001) ( Figure 5 ). We also observed frequent microscopic infiltrative growth into the adjacent muscle layer in PC3-ERK5 tumors, when compared to PC3-EmptyVector 7 out of 10 compared to 0 out of 9, respectively; Fishers' exact test, P ¼ 0.003 (twosided). Taken together, overexpression of ERK5 enhances in vitro and in vivo prostate carcinogenesis. 
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Inhibition of ERK1/2 activation alone is insufficient to decrease proliferation Preincubation of the EcR293 MEK5D stable clone with the small molecule inhibitor PD184352 prior to Ponasterone A induction of MEK5 led to inhibition of activation of ERK1/2 and ERK5. However, whereas 1-3 mM was sufficient to block the classical MAPK cascade, as judged by suppression of phosphorylation of ERK1/2, it was necessary to increase PD184352 concentration to 10 mM to suppress ERK5 activation, where ERK5 activation is judged by a decrease in its electrophoretic mobility (Mody et al., 2001) (Figure 6a) . A similar selective inhibition was seen in PC3 cells, at lower concentrations, where 0.3 mM PD184352 was sufficient to block ERK1/2 activation and 3 mM PD184352 was required to suppress ERK5 activity (data not shown). Further proliferation analyses were performed in untransfected PC3 cells, preincubated at low-dose 0.3 mM PD184352, sufficient to block ERK1/2 activation, and high dose 3 mM PD184352 required to block ERK1/2 and ERK5 activation. Blockade of activation of the classic MAPK pathway was found to cause a slight increase in cellular proliferation, but this increase did not quite reach statistical significance (P ¼ 0.0728). However, preincubation at the higher dose of the inhibitor significantly suppressed proliferation (Po0.0001) (Figure 6b ).
Discussion
Optimization and validation of ERK5 immunodetection were performed (Figures 1 and 3 ; Supplementary Figure  1) . Consistent with our recent findings on MEK5, here we report our original findings of ERK5 overexpression in a validated cohort of CaP specimens. We demonstrated a strong, linear correlation between MEK5 and ERK5 protein expression in matched cases (P ¼ 0.0053). 
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This close relationship ties in with current knowledge of ERK5 as the specific substrate for MEK5, and pMEK5 as the only known activating molecule of ERK5 (English et al., 1995; Mody et al., 2003) . We have demonstrated a significant correlation between ERK5 cytoplasmic overexpression and Gleason sum score (Po0.0001), an observation not seen for MEK5 expression (Mehta et al., 2003) . Taken together, these results suggest that ERK5 is the driving molecule in this pathway, with a closer correlation with clinical parameters than MEK5.
We also discovered a significant correlation between ERK5 cytoplasmic expression and the presence of bone metastases (P ¼ 0.0044), a key cause of morbidity (Bubendorf et al., 2000; Rubin et al., 2000) . It is therefore of interest that IL-6, a cytokine previously implicated in bony metastasis (Okamoto et al., 1997; Adler et al., 1999) , was found to activate ERK5 function in multiple myeloma cells (Carvajal-Vergara et al., 2005) . In addition, this study shows that increased cytoplasmic ERK5 expression correlates with a less favorable disease-specific survival, comparing low-and intermediate-expression groups with the high expression group (P ¼ 0.036, Kaplan-Meier and log-rank analyses). It will now be important to extend our observation to test if the role of ERK5 overexpression in CaP is confirmed using tumor materials from other institutions, including series that are obtained in the post-PSA testing era, which would have a higher percentage of lower Gleason grade tumors. Another important finding is revealed in matched tumor pairs (androgen responsive and androgen refractory, respectively): the presence of ERK5 nuclear expression is significantly associated with the transition from hormone-sensitive to hormoneinsensitive disease (P ¼ 0.0078). Of particular interest is the finding that the presence of strong nuclear ERK5 expression was shown to have a significant association with poorer patient prognosis (Po0.0001). Strong nuclear ERK5 expression retains this significant association with survival, irrespective of Gleason grade (P ¼ 0.0008) or presence of strong ERK5 cytoplasmic intensity (P ¼ 0.0052), and in multivariate analysis, by Cox regression, ERK5 nuclear expression is an independent prognostic marker in CaP (Po0.0001). It is also worth noting that upon cotransfection of ERK5 and MEK5D into PC3 cells, ERK5 protein accumulates significantly within the nucleus. Using indirect immunofluorescence, endogenous ERK5 proteins in PC3, LNCaP and LNCaP-AI cells appeared to reside predominantly within the cytoplasm. Hence, although the in vitro LNCaP-AI cells have acquired a phenotype of relative androgen independence, it does not fully reflect the state of clinical androgen-refractory disease where ERK5 overexpression was noted to be predominantly located at the nucleus. Data from in vitro study suggested that simultaneous activation of MEK5 and ERK5 (or adequate growth environment) is adequate to drive ERK5 into nucleus. Hence, the functional and transcriptional impacts of ERK5 activation with and without synchronous MEK5 activation in the context of nuclear ERK5 warrant further research.
Unlike the smaller ERK1/2, ERK5 requires active transport to enter and exit the nucleus. Using GFP-ERK5 fusion protein, our data support the model of cytoplasmic ERK5 in quiescent cells translocating to the nucleus in the presence of activated MEK5 (Buschbeck and Ullrich, 2005; Kondoh et al., 2006) . Interaction between the N and C termini is essential for cytoplasmic retention of ERK5, while activating phosphorylation of the N-terminal half by MEK5 disrupts the binding and promotes ERK5 nuclear import. In this study, we have identified a subgroup of patients with strong nuclear ERK5 expression and very poor survival. The exact mechanism of nuclear ERK5 in CaP is of great interest both biochemically and clinically. Interaction between ERK1/2 and ERK5 has previously been suggested (Mody et al., 2001) , an observation further supported by enhanced nuclear accumulation of ERK5 in NIH3T3 cells following suppression of ERK1/2 by 1 mM PD184352 (an MEK1/2 inhibitor) (Barros and Marshall, 2005) . Interestingly, ERK1/2 activation is reported in early CaP while subsequent inactivation of ERK1/2 is contemporaneous with the emergence of the poorly differentiated, metastatic phenotype (Uzgare et al., 2003) . Our data support these observations: treatment with lowdose PD184352, sufficient to block ERK1/2 activation, did not suppress proliferation-cell proliferation actually increased, though not reaching statistical significance (P ¼ 0.0728). Preincubation of prostate cells with higher dose of PD184352 sufficient to block ERK5 significantly inhibits proliferation (Po0.0001). This point is even more pertinent in light of the findings of Hayashi et al. (2005) , who raised the possibility that attenuation of the MEK5/ERK5 signaling pathway may also contribute to the antitumor effect of these compounds because the MEK5/ERK5 pathway also modulates neoangiogenesis (Hayashi et al., 2005) . A possible follow-on approach would be to utilize siRNA technology to test the biological effects of ERK5 knockdown in CaP.
Given the mitotic effect of MEK5/ERK5 signaling in CaP, we explored its link with DNA replication licensing factors using a combination of clinical samples and in vitro cell model (Dudderidge et al., 2007) . Significant associations between Gleason grade and the number of cells traversing G 1 phase was observed (P ¼ 0.001), with high ERK5 levels associated with both an increase in replication licensed but noncycling cells (Mcm2 þ ve/Ki67Àve; P ¼ 0.01) and accelerated cell cycle progression (shortened G 1 phase; P ¼ 0.005), phenotype consistent with increasing proliferative potential.
In this study, we have discovered a close association between ERK5 expression and adverse clinical parameters in human CaP. The finding of strong nuclear ERK5 staining and its positive correlation with less favorable disease survival and androgen-independent disease opens up another field in the elucidation of our understanding of the role of the MEK5/ERK5 pathway in CaP. Further studies are required to clarify the mechanism and consequences of ERK5 nuclear localization. Of clinical importance, here ERK5 nuclear staining has been shown to be an independent marker of prognosis in CaP, and may prove useful as a stratification tool to identify a more aggressive/metastatic phenotype.
Materials and methods
Human prostate tissue samples
For immunohistochemical studies of ERK5 expression in hormone naive CaP, ethics committee approval and the consent of patients with CaP diagnosed on prostatic biopsy, and patients undergoing transurethral prostatectomy (TURP) for obstructive symptoms, subsequently diagnosed with CaP on histological examination, were obtained over a 6-year period from 1989 to 1995. Specimens containing greater than 75% tumor involvement were selected for analysis. The primary immunohistochemical analysis included 81 patients with CaP, median age 73 years (range 55-90) and median Gleason sum score 8 (range 5-10). At the commencement of our study, 58 (72%) patients had died and 18 (22%) were alive. Survival times for five patients were unknown, and these patients were excluded from the survival analysis. For survivors, the mean follow-up period was 71.6 months (5 days to 142 months, s.d. ¼ 55.4). A total of 20 cases of BPH specimens collected in exactly the same manner, via TURP, were studied as controls. Formalin-fixed and paraffin waxembedded specimens were obtained at the time of diagnosis, following TURP, prior to any androgen ablation. The secondary immunohistochemical analysis included 26 patients (52 matched tumors), all of which had received conventional androgen-deprivation therapy (orchidectomy, antiandrogens or androgen ablation therapy). Patients were selected for treatment if they initially responded to treatment (response was defined by PSA levels falling by at least 50%), but subsequently relapsed. Patients were classed as having hormone-escaped cancer when sustained rising PSA levels were noted and were selected for study if a post-hormone relapse sample was available (Bartlett et al., 2005) .
Immunohistochemical analysis
Polyclonal anti-ERK5, raised in sheep as previously described (Mody et al., 2001 ) and polyclonal anti-MEK5 (Stressgen, San Diego, CA, USA) were optimized for immunohistochemical analysis (data not shown). Archive paraffin wax-embedded serial sections (4 mm) taken from clinical prostate samples were prepared and incubated with the desired antibody overnight at 4 1C and immunohistochemical analysis was performed as described previously (Gnanapragasam et al., 2003) . The staining was developed with diaminobenzidine tetrahydrochloride (Sigma-Aldrich, UK), with hematoxylin used as a counterstain. Heart muscle was used as a positive control; no primary antibody as a negative control. Additional control experiments were performed using cell pellets obtained from PC3-ERK5 and PC3-EmptyVector cells to represent varying levels of ERK5-expressing cells.
All slides were assessed by two independent observers (MM and SMcC) with 100% interobserver agreement on the grading system confirmed in the first 20 cases. Both observers were blinded to the clinical details for these cases prior to evaluation. The cytoplasmic immunoreactivity signals were correlated with ERK5 expression and scored as either absent (0), weak (1), moderate (2) or strong (3) as previously published (Armes et al., 1999; Bouras et al., 2001) . Nuclear immunoreactivity signals were scored as either positive or negative.
Cells and cell culture
The PC-3 cell line (passage 27) was purchased from the European Collection of Animal Cell Cultures (Salisbury, UK) and was maintained in growth medium (RPMI 1640; Gibco BRL, Invitrogen, Paisley, UK), containing 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (25 mM) and L-glutamine (20 mM), supplemented with 10% heat-inactivated fetal calf serum (FCS, Sigma-Aldrich, Dorset, UK), 100 units per ml penicillin, and 100 mg ml À1 of streptomycin (Gibco BRL); this was referred to as full medium. Androgen-independent LNCaP cells (LNCaP-AI) were derived in house from LNCaP cells, following continuous passaging in an environment depleted of androgens for a period of over 9 months. The LNCaP-AI cell line did not require androgen to proliferate, however the cells were still responsive to androgen stimulation. Passage number-matched parental LNCaP cells were also maintained.
Plasmids and generation of stable clones ERK5 was amplified from a full-length clone (23) using oligonucleotides MP405 (GGATCCGCCGAGCCTCTGAA GGAGGAAG) and MP1310 (GCGGATCCTCAGGGGT CCTGGAGGTCAGG) with GC-Rich PCR System (Roche, UK). The resulting fragment was cloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA), sequenced and then subcloned into EGFP-C1 (Clontech, Mountain View, CA, USA) to form enhanced green fluorescent protein (EGFP)-C1 ERK5.
A constitutively active mutant of MEK5 (MEK5D-HA) was obtained from Dr JD Lee (Department of Immunology, The Scripps Research Institute, USA) and inducible 293 cells expressing MEK5D were generated as previously described (Mehta et al., 2003) .
PC3 cells overexpressing ERK5 were generated by transfection with EGFP-C1 ERK5 using Superfect Transfection Reagent (Qiagen, Crawley, UK) according to the manufacturer's recommendations. Following selection with geneticin (G418, 1 mg ml
À1
; Sigma-Aldrich), colonies were left to form for 2-3 weeks. Control stable cell lines were similarly established with the vector (EGFP-C1) alone. Individual colonies were subcultured and screened for ERK5 expression by western analysis. Presence and subcellular localization of ERK5 was also confirmed by fluorescent microscopy.
Xenograft tumor formation A total of 7.5 Â 10 6 PC3-ERK5 cells or control PC3-EmptyVector cells were each suspended in 50 ml of 10% FCS supplemented media and injected subcutaneously into the flanks of 6-week-old nude mice (10 mice per construct). From the moment of injection the animals were inspected regularly Fluorescent microscopy PC3 cells were plated on sterile coverslips placed in six-well culture dishes and cultured in the desired condition for 48 h. Cells were washed in phosphate-buffered saline, fixed with methanol for 20 min at À20 1C and allowed to air dry. The coverslips were mounted on microscope slides using an antiphotobleaching solution, Vectashield (Vector Laboratories, Peterborough, UK), which contains the nuclear stain diamino-2-phenylindole. The slides were then viewed using a Leica DMR/HCS microscope ( Â 100 magnification; Leica Microsystems Ltd., Milton Keynes, UK). Photographs were taken with a SPOT digital camera and software (version 3.5.2 for Windows; Diagnostic Instruments Inc., MI, USA).
Western blotting
Cultured cells were lysed directly on plates with 6 Â sodium dodecyl sulfate sample buffer containing 10% b-mercaptoethanol. Samples were denatured and analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by transfer to nitrocellulose. Antibodies were used at the following dilutions: anti-ERK5, 1:1000; and anti-a tubulin, 1:2000 (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated secondary antibodies (Dako, High Wycombe, UK) were applied at 1:500 dilution and detected using enhanced chemiluminescence detection kit (Amersham, Piscataway, NJ, USA).
WST-1 proliferation assay WST-1 assays were carried out according to the manufacturer's instructions (Roche). PC3 cells were seeded in 96-well, flatbottom tissue culture plates at a density of 5000 cells per well in a final volume of 100 ml per well culture medium at 37 1C, 5% CO 2 . After 48 h, WST-1 reagent was added at a volume of 10 ml per well and the cells were incubated for up to 3 h. Absorbance at 450 nm was measured using a microplate reader (Bio-Rad Laboratories Ltd., Model 680). Each assay was conducted in sets of 10 and the experiment was repeated three times. Control wells were containing culture medium and WST-1 reagent, but no cells were included to determine background fluorescence.
Cell migration and invasion
Overnight serum-starved PC3 cells were trypsinized and washed twice with serum-free medium (RPMI 1640 containing 2 mM glutamine and 100 U ml À1 Pen per 100 mg ml À1 Strep) containing 0.5% bovine serum albumin. Cells were plated out in 0.8 mm pore migration chambers in triplicate (for migration-Becton Dickinson Labware catalog no. 3097) at a density of approximately 2.5 Â 10 4 cells per well in 300 ml of serum-free medium. As a chemoattractant, 600 ml of full medium was added to the lower chamber (Becton Dickinson Labware catalog no. 353504). Cells were allowed to attach and migrate overnight at 37 1C under 5% CO 2 /95% air atmosphere. After 16-18 h, the medium was aspirated and the cells on the upper side of the membrane were removed with a cotton swab. The migrated cells were then fixed with methanol, stained with hematoxylin and counted under a light microscope at Â 20 magnification. For invasion assays, the same protocol was employed with Biocoat Matrigel invasion chambers in duplicate (Becton Dickinson Labware catalog no. 354480). Each experiment was repeated at least three times and each time the mean numbers of migrated or invading cells were taken from three chambers.
Statistical analysis
The statistical significance of trends between ERK5 expression and standard prognostic variables was assessed using the Mann-Whitney U-test and Kruskal-Wallis test (Table 1) . Linear regression analysis was employed to evaluate correlation of ERK5 and MEK5 expression. Correlation of ERK5 expression and patient survival was analysed using the Kaplan-Meier method with log-rank testing. Multivariate analysis was performed using the Cox regression model for survival data. Wilcoxon matched-pairs test was used for matched tumor samples. All these tests were undertaken using SPSS, version 11.0, computer software (SPSS Inc.). A P-value of o0.05 was taken to indicate statistical significance.
